Journal: Biomedicines

Article Title: A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment

doi: 10.3390/biomedicines9070806

Figure Lengend Snippet: Immunization with rSur-FLIPr induces antitumor immunities through CD8- and TAP-dependent pathways. ( a ) Groups of C57BL/6 mice ( n = 5) were immunized with rSur or rSur-FLIPr twice at a two-week interval (30 µg per dose). Mice injected with PBS served as the controls. ( b ) C57BL/6 mice were immunized with rSur-FLIPr twice at a two-week interval (30 µg per dose). One day before tumor implantation, the mice were randomly divided into two groups ( n = 10) and then were intraperitoneally injected with anti-CD4, anti-CD8, or isotype control antibodies. ( c ) C57BL/6- or TAP-deficient mice ( n = 5/group) were immunized with PBS or rSur-FLIPr (30 µg per dose) twice at a two-week interval. Seven days after the second immunization, the animals were subcutaneously inoculated with EG7 cells (5 × 10 4 /mouse). Tumor growth was monitored after challenge. The data are expressed as the means ± SEM.

Article Snippet: EG7 cells (Bioresource Collection and Research Center, Hsinchu, Taiwan, BCRC Number: 60418) were cultured in RPMI 1640 medium supplemented with 10% ( v / v ) heat-inactivated fetal bovine serum, L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES (10 mM), G418 (0.4 mg/mL), 2-mercaptoethanol (0.05 mM), and penicillin/streptomycin (50 units/mL) at 37 °C under 5% CO 2 .

Techniques: Injection, Tumor Implantation, Control

Journal: Biomedicines

Article Title: A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment

doi: 10.3390/biomedicines9070806

Figure Lengend Snippet: A combination of chemotherapy with rSur-FLIPr enhances the antitumor effects. Groups of C57BL/6 mice ( n = 5) were subcutaneously inoculated with 5 × 10 4 EG7 ( a , b , e , f ) or 1 × 10 5 B16F10 ( c , d , g , h ) cells on day 0. The animals were treated with PBS, rSur, or rSur-FLIPr on day 3 and 10 ( a , b , c , d ). Tumor-bearing mice were treated with cyclophosphamide on day 10, 12, and 14 (3 mg per dose) plus rSur-FLIPr (30 µg per dose) or PBS on day 17 and 24 ( e , g , f , h ). Tumor growth ( a , c , e , g ) and survival rate ( b , d , f , h ) were monitored. The results are one of two representative experiments. After treatment with cyclophosphamide plus rSur-FLIPr, tumor-free mice ( n = 9) that survived for 100 days were rechallenged with EG7 cells. Tumor growth ( i ) and survival rate ( j ) were monitored. The statistical significance was determined using the log-rank (MauteeCox) test. * p < 0.05, ** p < 0.01, and *** p < 0.001.

Article Snippet: EG7 cells (Bioresource Collection and Research Center, Hsinchu, Taiwan, BCRC Number: 60418) were cultured in RPMI 1640 medium supplemented with 10% ( v / v ) heat-inactivated fetal bovine serum, L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES (10 mM), G418 (0.4 mg/mL), 2-mercaptoethanol (0.05 mM), and penicillin/streptomycin (50 units/mL) at 37 °C under 5% CO 2 .

Techniques:

Journal: Biomedicines

Article Title: A Novel Recombinant Fcγ Receptor-Targeted Survivin Combines with Chemotherapy for Efficient Cancer Treatment

doi: 10.3390/biomedicines9070806

Figure Lengend Snippet: Preexisting anti-FLIPr antibodies do not diminish the antitumor capacity induced by rSur-FLIPr. The experimental flow chart is shown ( a ). Groups of C57BL/6 mice were immunized twice at a two-week interval by subcutaneous injection without/with rFLIPr plus aluminum on day -32 and -18. The mice in each group were randomly divided into 2 subgroups and treated with PBS or rSur-FLIPr at day 3 and 10 after EG7 inoculation. The sera were collected on day -32 (baseline) and -4 (after the second immunization). The anti-FLIPr antibody titers were determined by ELISA ( b , c ). The tumor volume was calculated as length × width × width/2 (mm 3 ) ( d , e ). The data are expressed as the means ± SEM. The statistical significance was determined using the Mann–Whitney test. ** p < 0.01. The results are one of two representative experiments.

Article Snippet: EG7 cells (Bioresource Collection and Research Center, Hsinchu, Taiwan, BCRC Number: 60418) were cultured in RPMI 1640 medium supplemented with 10% ( v / v ) heat-inactivated fetal bovine serum, L-glutamine (2 mM), sodium pyruvate (1 mM), HEPES (10 mM), G418 (0.4 mg/mL), 2-mercaptoethanol (0.05 mM), and penicillin/streptomycin (50 units/mL) at 37 °C under 5% CO 2 .

Techniques: Injection, Enzyme-linked Immunosorbent Assay, MANN-WHITNEY